Immunogenicity of Tetravalent Protein Vaccine SCTV01E-2 against SARS-CoV-2 EG.5 Subvaraint: A Phase 2 Trial

The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become the dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its immunogenicity against Omicron EG.5, comparing it with its progenitor...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jihai Tang, Qinghua Xu, Chaoyin Zhu, Kun Xuan, Tao Li, Qingru Li, Xingya Pang, Zhenqiu Zha, Jinwei Li, Liyang Qiao, Haiyang Xu, Gang Wu, Yan Tian, Jun Han, Cuige Gao, Jiang Yi, Gui Qian, Xuxin Tian, Liangzhi Xie
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2024-02-01
Sarja:	Vaccines
Aiheet:	safety immunogenicity SARS-CoV-2 multivalent vaccine booster
Linkit:	https://www.mdpi.com/2076-393X/12/2/175
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!